
Wildfires: How to cope when smoke affects air quality and health

What can magnesium do for you and how much do you need?

Dry socket: Preventing and treating a painful condition that can occur after tooth extraction

What happens during sleep � and how to improve it

How is metastatic prostate cancer detected and treated in men over 70?

Could biofeedback help your migraines?

What is autism spectrum disorder?

Plantar warts: Options for treating this common foot condition

Cancer survivorship: What comes next after treatment

Nutritional yeast: Does this savory, vegan seasoning pack a nutritional punch?
Cancer Archive
Articles
What is a synthetic human genome?
A group of scientists wants to develop technology to create a synthetic human genome, which could lead to improved organ transplantation, vaccines and medicines, and to new ways to fight cancer and infections.
More evidence that a healthy lifestyle might help prevent cancer
It appears that four healthy habits—getting 150 minutes of moderate-intensity exercise per week, maintaining a body mass index between 18.5 and 27.5, no smoking, and drinking only in moderation—may prevent many cancer cases and death in white people.
Harvard study links aspirin therapy and cancer prevention
News Briefs
Image: DimaSobko/Thinkstock
A Harvard study published March 3, 2016, in JAMA Oncology adds to increasing evidence that aspirin use may help stave off colorectal cancer and suggests that aspirin is also associated with a small reduction of overall cancer risk.
Researchers looked at aspirin use among almost 136,000 men and women in two studies over 32 years. They noted that regular aspirin use—taking either a 325-mg tablet or an 81-mg tablet two or more times per week—was associated with a 3% reduction in cancers over all, although they saw no effect on major cancers like those of the breast, prostate, or lung. The researchers say the overall reduction was due mostly to a 15% risk reduction for gastrointestinal cancer and a 19% risk reduction for colorectal cancer.
The risks of active surveillance for men with intermediate-risk prostate cancers
Many men with prostate cancer benefit from active surveillance, in which treatment doesn’t begin unless the cancer spreads. There has been some debate about whether this strategy is safe for men with intermediate-risk prostate cancer. A new study suggests that this type of cancer is more likely to spread than previously thought â€� but active surveillance can still be a good option for many intermediate-risk men.
Do you really need that cancer screening?
Image: Thinkstock
A research letter published online Jan. 21, 2016, in JAMA Oncology suggests that many older adults are getting unnecessary cancer screenings. Researchers looked at questionnaire answers from about 150,000 seniors (ages 65 or older) across the country, and found that about half had received prostate-specific antigen (PSA) testing or mammography in the past year. But a third of those screened did not have a 10-year life expectancy, a major guideline for screening. Unnecessary screening rates varied by state—for example, 11% in Colorado and about 20% in Georgia. "Undergoing a screening test may actually cause more harm than good, especially with older patients or those with significant medical conditions," says Dr. Marc Garnick, an oncologist at Beth Israel Deaconess Medical Center and editor in chief of Harvard's Annual Report on Prostate Diseases. So talk to your doctor about the guidelines. Both the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF) recommend routine mammograms every two years for women ages 55 to 74. The ACS does not recommend mammograms in this age group if a woman has a life expectancy of less than 10 years.
For all men, the USPSTF recommends against routine PSA testing. The ACS suggests that men 50 or older (at average risk for prostate cancer) make the decision about screening with their doctor, but only if they have a life expectancy of at least 10 years, and only if they have been advised about the uncertainties, risks, and potential benefits of prostate cancer screening.
Cancer survivors may face cardiovascular complications
Even the newer, targeted cancer therapies may harm the heart.
Image: Bigstock
About 14 million people in the United States are living with cancer, a number that reflects the steady rise in cancer survivorship in recent decades. In 1980, only about half of people with cancer lived five years after diagnosis. Today, five-year cancer survival rates are greater than 70%.
Unfortunately, many cancer-suppressing treatments can have undesirable effects on the heart and blood vessels. The increasing awareness of these effects—coupled with the surge of older people being diagnosed with and surviving cancer—has spurred a new specialty known as cardio-oncology. Experts in this burgeoning field focus on promoting heart health in people with cancer, both during and after their treatment.
Breast cancer: The good news
Personalizing breast cancer diagnosis and treatment has resulted in therapies that are more effective and less toxic than in the past.
Image: Thinkstock
The federal government's "Cancer Moonshot," with the expressed goal of curing cancer, is getting a lot of press lately. While the initiative's stated goal may be overly ambitious because cancer is actually 200 or more individual diseases, it promises to increase research funding and speed the availability of new treatments.
Amid the excitement, it's easy to overlook the fact that there has already been great progress in treating many cancers. Patients are enduring fewer side effects and living longer. Breast cancer is a prime example. "There's no question that breast cancer treatment is improving," says Dr. Ann Partridge, senior physician at the Susan F. Smith Center for Women's Cancers at Harvard-affiliated Dana-Farber Cancer Institute.
Ask the doctor: Concern about a now "normal" PSA
Ask the doctor
Q: I am 68 years old, and recently my PSA level (which was normal before) increased to 5.2 nanograms per milliliter (ng/ml). My doctor repeated the test one month later, and it was normal again at 3.3 ng/ml. Should I still be concerned?
A: One of the reasons that routine PSA testing is so controversial is the inability of the test to distinguish men with prostate cancer from those without it. A common cutoff is 4 ng/ml, but this is hardly a black-and-white answer. In fact, 30% of men with a PSA result between 4 and 10 have cancer. (The remaining 70% have benign causes, like an enlarged prostate.) In men with a "normal" PSA in the 2-to-4 range, 20% have cancer. So the risk is still present.

Wildfires: How to cope when smoke affects air quality and health

What can magnesium do for you and how much do you need?

Dry socket: Preventing and treating a painful condition that can occur after tooth extraction

What happens during sleep � and how to improve it

How is metastatic prostate cancer detected and treated in men over 70?

Could biofeedback help your migraines?

What is autism spectrum disorder?

Plantar warts: Options for treating this common foot condition

Cancer survivorship: What comes next after treatment

Nutritional yeast: Does this savory, vegan seasoning pack a nutritional punch?
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!
Sign Up